tbuckley/cabot-search huggingface dataset:
PB2366 LOW DOSE CYCLOPHOSPHAMIDE CONDITIONING REGIMEN IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IS WORTH EXPLORING IN THE TREATMENT OF ACQUIRED APLASTIC ANEMIA
Authors: S. Cui, F. Kong, Y. Fang, X. Cui, Y. Wang, J. Wang, K. Liu, S. Ding, M. Shen, R. Xu
Journal: HemaSphere (2019)

Background: In recent years, haploid hematopoietic stem cell transplantation has made great progress in the treatment of acquired aplastic anemia, but the incidence of transplant related complications and transplant related mortality are still high, and the conditioning reginem needs to be further optimized. Aims: To investigate the safety and efficacy of haploidentical hematopoietic stem cell transplantation with different intensity conditioning regimen in the treatment of aplastic anemia (AA). Methods: 27 AA patients who underwent haploidentical transplantation in Affiliated Hospital of Shandong University of Traditional Chinese Medicine from July 2017 to July 2018 were enrolled. All patients received bone marrow plus peripheral blood stem cells.According to the dosage of cyclophosphamide in the conditioning regimen, 26 patients excluding one other conditioning regimens were divided into high‐dosage group (regimen 1, 16 cases) and low‐dosage group (regimen 2, 10 cases). The data of Engraftment, graft‐vs‐host disease (GVHD), hematopoietic reconstitution, relapse, infection, overall survival (OS) were analyzed. The comparison between the two groups was tested by χ(2) test. Results: ALL patients achieved primary engraftment. The activation rate of CMV and EBV was 63 % (17/27). Post‐transplant lymphocyte disease (PTLD) in 0 case. The cumulative incidences of acute GVHD grade I‐IV and chronic GVHD were 22.2% (6/27) and 18.5% (5/27) respectively and the incidence of extensive chronic GVHD was 0%. The median follow‐up time was 6.5 (0.5‐12.5) months, the OS was 96.3% (26/27). All survived patients were no longer dependent on blood transfusion and none of them had recurrence. Comparing the rates of overall survival(94%(15/16) vs.100%(10/10)) and rates of chronic GVHD(18.8%(3/16) vs. 20%(2/10)) in regimen 1 and regimen 2 group, there were no significant difference ( P &gt; 0.05). Significant difference was found at the incidence of I‐IV acute GVHD (12.5% (2/16) vs. 30% (3/10), P &lt; 0.05). Summary/Conclusion: Haploidentical hematopoietic stem cell transplantation is effective and safe in the treatment of acquired aplastic anemia. It is suitable for patients who are not eligible for matched donor transplantation. Application of low dose cyclophosphamide preconditioning in haploid transplantation is worth exploring.
THU0462 OUTCOME PREDICTION FOR TREATMENT OF KNEE OSTEOARTHRITIS WITH A TOTAL KNEE ARTHROPLASTY. DEVELOPMENT AND VALIDATION OF A PREDICTION MODEL FOR PAIN AND FUNCTIONAL OUTCOME USING THE DUTCH ARTHROPLASTY REGISTER (LROI) DATA
Authors: J.J. Tolk, J.H. Waarsing, R.P.A. Janssen, L.N. van Steenbergen, S.M.A. Bierma-Zeinstra, Max Reijman
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> One of the main determinants of treatment satisfaction after total knee arthroplasty (TKA) is the fulfilment of preoperative expectations. For optimal expectation management it is useful to be able accurately predict the treatment result. Multiple patient factors that are obtained for registration in the Dutch Arthroplasty Registry (LROI) are associated with the treatment result. Therefore, these factors can potentially be utilised to estimate the most likely outcome on pain and functional outcome for an individual patient <h3>Objectives</h3> The aim of the present study was to create and validate models that predict residual symptoms on 10 specific outcome parameters at 12-month follow-up for patients undergoing primary TKA for knee osteoarthritis. <h3>Methods</h3> Data was extracted from the LROI on TKA patients who had pre- and postoperative PROMs registered in the LROI registry. Multiple logistic regression analyses were performed to construct predictive algorithms for satisfaction, treatment success, and residual symptoms concerning pain in rest and during activity, sit-to-stand movement, stair negotiation, walking, performance of activities of daily living, kneeling and squatting. Models were developed for men and women separately. We assessed predictive performance by examining measures of calibration and discrimination. <h3>Results</h3> Data of 7071 patients could be included for data analysis. Residual complaints on kneeling (♀72%/ ♂59%) and squatting (♀71%/ ♂56%) were reported most frequently, and least residual complaints were scored for walking (♀16%/ ♂12%) and pain in rest (♀18%/ ♂14%). The predictive algorithms for residual symptoms concerning sit-to-stand movement, stair negotiation, walking, activities of daily living and treatment success showed acceptable discriminative values (AUC 0.68 – 0.74). The prediction models for residual complaints regarding kneeling, squatting, pain and satisfaction showed the least favourable results (AUC 0.58 – 0.64). The calibration curves showed adequate calibration for most of the models. <h3>Conclusion</h3> A considerable proportion of patients has residual complaints after TKA. The present study showed that demographic and PROMs data collected for the LROI registry, can be used to predict the chance for residual symptoms after TKA. The predictive models that have been developed can be useful for individual expectation management in patients planned for TKA for knee osteoarthritis. <h3>Acknowledgement</h3> This study was supported by a grant from the Van Rens Foundation, and conducted with data of the Dutch Arthroplasty Registry. <h3>Disclosure of Interests</h3> None declared
Reproducibility of Atrial Fibrosis Assessment Using CMR Imaging and an Open Source Platform
Authors: Iain Sim, Orod Razeghi, Rashed Karim, Henry Chubb, John Whitaker, Louisa O’Neill, Rahul K. Mukherjee, Caroline H. Roney, Reza Razavi, Matthew Wright, Mark O’Neill, Steven Niederer, Steven E. Williams
Journal: JACC. Cardiovascular imaging (2019)
AB0749 ARE THERE ANY DIFFERENCES IN THE EFFECTIVITY AND SAFETY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH PSORIATIC ARTHRITIS ACCORDING THEIR GENDER?
Authors: Rosa García, Manuel Fernandez-Prada, Arantxa Conesa, Jose Campos Esteban, Ana Urruticoechea-Arana, Alejandro Olive, Silvia Paredes, Delia Taverner, Carlos Gonzalez
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Gender-related biochemical, hormonal and psychological factors could play an important role in the response to TNF blocker therapy in psoriatic arthritis (PsA). Scarce data are available analyzing differences in effectiveness and safety of the antiTNFs, and none in particular with Certolizumab Pegol (CZP) according to the gender. <h3>Objectives:</h3> To evaluate the influence of the gender in the effectiveness and safety of CZP in the routine clinical setting in PsA patients. <h3>Methods:</h3> Observational, national and muticentric cohort (approved by local ethical committee), PsA patients treated with CZP according to routine clinical practice were studied for 12 months. Clinical and disease characteristics and disease activity between gender were compared. Safety analysis: adverse events and withdrawn. <h3>Results:</h3> 347 PsA patients were analyzed. No statistical differences were found between women and men at baseline in demographics, clinical variables, except for previous biologic treatment and ESR (Table 1). In both genders, a statistical significant decreased was observed after 1 year of CZP treatment in the following variables: DAS28(CRP); SJC; TJC; PGA (patient global ssesment);% patients with enthesitis, dactilytis and nail disease; but with no differences between females and males. Variables that influence the response at 12 months are: disease duration, CRP and TJC at baseline. Drug survival of CZP was 80.1%, and no differences were observed in gender. Adverse events related to CZP were observed in 9.5% and 19.9% withdrawn treatment: 12.4% due to lack of effectiveness, 4.0% due to intolerance and 3.5% other reasons. <h3>Conclusion:</h3> CZP has shown to be effective and safe in PsA patient after a year of treatment in clinical practice regardless patient’s gender. <h3>Disclosure of interests:</h3> Rosa García : None declared, Manuel Fernandez-Prada: None declared, arantxa Conesa: None declared, Jose Campos Esteban: None declared, aNA URRUTICOECHEA-ARANA: None declared, alejandro Olive: None declared, SILVIA PAREDES Speakers bureau: Bristol, Roche, amgen, Pfiser, abbvie, lilly, UCB, Delia Taverner Speakers bureau: amgen, pfiser, Bristol, Lilly, Roche, Carlos Gonzalez Consultant for: Celgene, Gilead, Janssen, Merk, Novartis, Pfizer, Speakers bureau: Celgene, Roche, UCB
Long-term quality of life in patients with breast cancer according to sentinel lymph node biopsy or axillary lymph node dissection: A multicenter cohort study with 6 years follow-up.
Authors: Tienhan Sandrine Dabakuyo, Emmanuel De Gournay, Aurelie Guyomard, Stephanie Boulet, Patrick Arveux, Sylvain Causeret, Sebastien Gouy, Marie-Martine Padeano, Catherine Loustalot, Marc Smail, Jean-Marc Sauzedde, Jean-Philibert Combier, Patrick Chevillote, Christian Rosburger, Franck Bonnetain, Charles Coutant, Jean Fraisse
Journal: Journal of Clinical Oncology (2013)

1114 Background: the aim of this study was to assess long term quality of life (QoL) over a period of 6 years in women with a breast cancer (BC) who underwent sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or SLNB followed by ALND. Methods: The EORTC-QLQ-C30 and the EORTC-QLQ-BR-23 questionnaires were used to assess QoL before surgery, just after surgery, 6, 12 and 72 months later. The Kruskal Wallis test with the Bonferroni correction was used to compare scores. A mixed model analysis of variance for repeated measurements was then applied to assess the longitudinal effect of surgical modalities on QoL. Results: Five hundred and eighteen BC patients were initially included. The median follow-up was 6 years. During the follow-up, 61 patients died. None of the patients of the SLNB group has developed lymphedema during follow-up and the relapse rate was not different between the different groups (p=0.62). Before surgery, global health (GHS) (P = 0.5226) and arm symptoms (BRAS) (P = 0.9902) QoL scores were similar whatever the surgical procedure. BRAS score (p=0.0001) was better in the SNLB group 72 months after surgery. Moreover, compared to ALND patients, patients treated with SLNB had fewer arm symptoms with the follow-up. In addition, body image (P = 0.0005), upset by hair loss (P = 0.0045), systemic therapy side effects (P = 0.0097) and future perspective (P = 0.0375) QoL dimensions remained better 5 to 6 years after diagnosis in patients treated by SLNB. Conclusions: Long term follow-up showed that, SLNB is a safe and acceptable accurate method associated with less morbidity than ALND.
PTH-132 Analysis of gastric ph by endofaster in combination with standard clinical parameters can predict response to ppi in patients with gastro-oesophageal reflux disease
Authors: J Hartley, A Rattan, B Alias, T Nuchcheddy-Grant, L Wernisch, A Hobson, M Di Pietro
Journal: Gut (2017)

Introduction  Up to 30% of patients with gastro-oesophageal acid reflux treated with acid suppressing drugs have pathological oesophageal acid exposure and symptoms on their own are poor predictors. Endofaster allows real time pH analysis of gastric juice during endoscopy. We hypothesised that in patients on proton pump inhibitors (PPI) or H2 receptor antagonists (H2RA) the presence of an acidic gastric pH at the time of the endoscopy, alone or in combination with other clinical factors, could predict response to medical therapy.  Method  This was a prospective cohort study. We recruited patients referred for OGD and on daily medical therapy with PPI or H2RA, with stable dose in the last 2 weeks. Patients who missed the last dose of medication prior to the OGD were excluded. Symptoms were assessed by validated questionnaire (GERD-Q). Single time-point reading of gastric pH was taken by Endofaster at OGD. Immediately after the endoscopy, patients received an ambulatory pH-impedance monitoring to assess 24 hour gastric and oesophageal acid exposure. Logistic regression was used to assess for relationships between 24 hour pH readings and other clinical parameters including gastric pH by Endofaster, endoscopic findings, dose of medications and symptom pattern.  Results  Of the 84 patients recruited 22 were excluded due to insufficient gastric juice at the time of the OGD, failure of pH-impedance or voluntary suspension of the PPI/H2RA. 77% of the patients were on PPI alone and the others either on H2RA or the combination of the two. In keeping with the previous evidence, 30% of the patients had pathological levels of oesophageal acid exposure. Single time-point gastric pH by Endofaster correlated significantly with 24 hour gastric pH (p=0.01), however, it did not correlate significantly with 24 hour oesophageal acid exposure (p=0.18). The logistic regression analysis identified 5 clinico-endoscopic factors that combined were predictive of 24 hour oesophageal pH (p=0.034). Endofaster pH, severity of heartburn and frequent acid taste positively correlated with oesophageal acid exposure, while high dose of PPI and frequency of heartburn were negative predictors.  Conclusion  These results indicate that in patients on acid suppressing therapy single time-point gastric pH in combination with other clinical factors can predict 24 hour acid exposure and aid clinical management.  Disclosure of Interest  None Declared
Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study
Authors: B. Ciseł, L. Pietrzak, W. Michalski, L. Wyrwicz, A. Rutkowski, E. Kosakowska, A. Cencelewicz, M. Spałek, W. Polkowski, M. Jankiewicz, R. Styliński, M. Bębenek, B. Kapturkiewicz, A. Maciejczyk, J. Sadowski, J. Zygulska, W. Zegarski, M. Jankowski, M. Las-Jankowska, Z. Toczko, U. Żelazowska-Omiotek, L. Kępka, J. Socha, E. Wasilewska-Tesluk, W. Markiewicz, J. Kładny, A. Majewski, W. Kapuściński, R. Suwiński, K. Bujko
Journal: Annals of Oncology (2019)
Abstract 14003: Outcomes With Invasive versus Conservative Management of Myocardial Infarction in Patients With Sepsis
Authors: Nathaniel R Smilowitz, Navdeep Gupta, Yu Guo, Sripal Bangalore
Journal: Circulation (2015)

Background: Patients hospitalized with sepsis may be predisposed to myocardial infarction (MI). The incidence, treatment, and outcomes of MI in sepsis have not been studied. Methods: We analyzed data from the National Inpatient Sample from 2002 to 2011 for patients with a diagnosis of sepsis (CCS category 2). The incidence of MI as a non-primary diagnosis was evaluated. Propensity score matching was performed (1:1, without replacement) to identify patients with secondary MI and sepsis who were managed invasively (defined as cardiac catheterization, percutaneous coronary intervention (PCI), or coronary artery bypass graft surgery (CABG)) or conservatively. The primary outcome was in-hospital all-cause mortality. Results: A total of 2,570,098 patients had a diagnosis of sepsis. MI developed in 118,183 (4.6%) patients, the majority with non-ST elevation MI (71.4%). In-hospital mortality was higher among patients with MI and sepsis than for those with sepsis alone (35.8% vs. 16.8%, p&lt;0.0001; adjusted OR 1.24, 95% CI 1.22-1.26). Among patients with MI, 11,899 (10.1%) underwent an invasive management strategy with revascularization in 4668 (39.2%). PCI was performed in 3,413 patients (73.1%), CABG in 1,165 (25.0%), and both CABG and PCI in 90 (1.9%) cases. Trends in mortality are shown in the Figure. In a propensity-matched cohort of 23,708 patients with MI, invasive management was associated with a lower mortality than conservative management (19.0% vs. 33.4%, p&lt;0.001; OR 0.47, 95% CI 0.44-0.50). In subgroups that underwent revascularization, the odds of mortality were consistently lower than corresponding matched subjects from the conservative group. Conclusions: Myocardial infarction frequently complicates sepsis and is associated with a significant increase in in-hospital mortality. Patients managed invasively had a lower mortality than those managed conservatively, and patients with MI complicating sepsis may warrant more aggressive management.
Abstract 17957: Obesity From Leptin Receptor Deficiency Provides Resistance to the Development of Pulmonary Hypertension
Authors: Vikram Gurtu, Adam Kinnaird, Spencer Proctor, Gopinath Sutendra, Evangelos Michelakis
Journal: Circulation (2016)

Introduction: Pulmonary arterial hypertension (PAH) is a proliferative vascular disease characterized by mitochondrial suppression in the pulmonary artery and right ventricle (RV), but also other s...
PS1510 FLUPENTIXOL MELITRACEN COMBINED WITH ONDANSETRON IN PREVENTION OF NAUSEA AND VOMITING INDUCED BY CONDITIONING IN PATIENT TO UNDERGO HSCT
Authors: Y. Lu, R. Fan, L. Kuang, B. Feng, Y. Shan
Journal: HemaSphere (2019)

Background: Nausea and vomiting are the most common complaints for patients with haematological neoplasia during conditioning. The risk of hematopoiesis stem cell transplantation (HSCT) always cause people in anxiety and depression, which add patients’ discomforts. Aims: The aim of this study is to observe the effect of lupentixol melitracen combined with ondansetron on nausea and vomiting. Methods: 160 patients with hematological neoplasia in the state of complete remission were included in this study. The patients were randomly divided into control group and lupentixol melitracen group. For patients in control group, they received recommended‐dose of ondansetron during conditioning each day. For patients in lupentixol melitracen group, they received lupentixol melitracen 10.5 mg combined with ondansetron each day. The incidence of nausea and vomiting was evaluated before, during and after chemotherapeutics infusion in the first day of conditioning. Results: Totally 158 patients, 78 in control group and 80 in lupentixol melitracen group could be evaluated. The difference of chemotherapy drug intensity in the two groups has no statistical significance (P &gt; 0.05). The incidence of nausea before, during and immediately after chemotherapeutics infusion was respectively 5.2%, 72.5%, 60.6% in the control group and 1.6%, 53.3%, 45.5% in the lupentixol melitracen group, and the difference was significant between the two groups (P &lt; 0.05). While the incidence of vomiting in the two groups has no significant difference (P &gt; 0.05). Summary/Conclusion: Flupentixol melitracen combined with ondansetron is more effective to prevent nausea than single ondansetron in patients during the first day of conditioning but no more effect on vomiting in our study.
Challenges of Personal Health Records—Reply
Authors: Christian Dameff, Brian Clay, Christopher A. Longhurst
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The impact of positive spousal support on trauma symptoms and sleep disturbance among prostate cancer survivors.
Authors: Charles Stewart Kamen, Anita Roselyn Peoples, Mohamedtaki Abdulaziz Tejani, Oxana Palesh, Karen Michelle Mustian, Luke Joseph Peppone, Michelle Christine Janelsins, Francis Kamen, Raymond S. Lord, Patrick J. Flynn, Matthias Weiss, David Spiegel, Gary R. Morrow
Journal: Journal of Clinical Oncology (2013)

9533 Background: Receiving a diagnosis of cancer can lead to psychological effects including symptoms of traumatic stress. Trauma symptoms can dysregulate sleep and sleep disturbance has been linked with negative health outcomes. Cancer-related trauma symptoms and sleep disturbance can affect the spouse of the cancer patient and the couple’s relationship; conversely, a supportive relationship can improve cancer survivors’ mental health. The impact of spousal support on trauma and sleep disturbance among prostate cancer survivors has not yet been examined. Methods: 315 prostate cancer survivors (mean age 66, 89% Caucasian), of whom 265 were married and 50 were unmarried (single, widowed, separated or divorced) completed the Impact of Events Scale (IES), Stanford Sleep Questionnaire, and a measure of positive spousal support. Data are self-report. Rates of trauma symptoms and sleep disturbance by marital status were compared using t-tests, and the contribution of marital status and spousal support to variance in these outcomes was evaluated using linear regression. Results: 13.4% of survivors reported significant (i.e., &gt;27 point IES cutoff) symptoms of traumatic stress and 23.2% reported moderate or higher rates of sleep disturbance. Trauma symptoms (t= -2.16, p&lt;.01) and sleep disturbance (t= -3.14, p&lt;.01) were significantly lower in married than unmarried survivors. Spousal support was negatively associated with trauma symptoms (r= -.18, p&lt;.01) and sleep disturbance (r= -.20, p&lt;.05), and inclusion of spousal support as a covariate rendered the linear relationship between marital status and both trauma symptoms and sleep disturbance non-significant (p&gt;.05). Conclusions: Spousal support is associated with reductions in trauma and sleep disturbance, over and above dichotomous marital status. This area needs further study, given high rates of trauma symptoms and difficulty disclosing health-related concerns among men with prostate cancer. Future research needs to explore mechanisms by which spousal support leads to improvement in trauma symptoms and sleep outcomes. Interventions bolstering spousal support could improve mental health in prostate cancer survivors.